Show simple item record

dc.contributor.authorAli, Esraa
dc.contributor.authorChean, Chung Shen
dc.contributor.authorKapoor, Bharat
dc.contributor.authorKumar, Periyasamy
dc.date.accessioned2024-04-03T14:15:20Z
dc.date.available2024-04-03T14:15:20Z
dc.date.issued2023-08
dc.identifier.citationChean, C. S., Ali, E., Kulkarni, P., Kapoor, B., & Kumar, P. (2023). Bilateral Persistent Placoid Maculopathy Following COVID-19 Vaccines: Real or Coincidence?. Ocular immunology and inflammation, 31(6), 1273–1278. https://doi.org/10.1080/09273948.2023.2170889en_US
dc.identifier.other10.1080/09273948.2023.2170889
dc.identifier.urihttp://hdl.handle.net/20.500.12904/18457
dc.description.abstractCOVID-19 vaccinations have been accompanied by reports of inflammatory uveitis. Herein, we report the first case of bilateral persistent placoid maculopathy (PPM) following COVID-19 vaccinations in a previously healthy 58-year-old man who presented with bilateral decrease in vision approximately 2 weeks after the second dose of AstraZenaca® ChAdOx1-S/nCoV-19 vaccine. Fundus examination revealed bilateral well-delineated whitish plaque-like macular lesions involving the fovea. Clinical and multimodal imaging findings were suggestive of PPM. Infective and autoimmune screen were all negative except for a raised MPO-ANCA. Medical review excluded systemic autoimmune and infectious diseases. Patient was monitored closely and his visual acuity improved and stabilised after a tapering regime of oral prednisolone. Mycophenolate mofetil was given as long-term steroid sparing immunosuppression. Our case demonstrated a likely localised autoimmune inflammatory response to the COVID-19 vaccine affecting choriocapillaris. Further research is needed to clarify the association between COVID-19 vaccines and inflammatory placoid lesions of the retina.
dc.description.urihttps://www.tandfonline.com/doi/full/10.1080/09273948.2023.2170889en_US
dc.language.isoenen_US
dc.subjectCOVID-19en_US
dc.subjectpersistent placoid maculopathyen_US
dc.subjectvaccineen_US
dc.titleBilateral persistent placoid maculopathy following COVID-19 vaccines: real or coincidence?en_US
dc.typeArticleen_US
rioxxterms.funderDefault funderen_US
rioxxterms.identifier.projectDefault projecten_US
rioxxterms.versionNAen_US
rioxxterms.versionofrecordhttps://doi.org/10.1080/09273948.2023.2170889en_US
rioxxterms.typeJournal Article/Reviewen_US
refterms.panelUnspecifieden_US
html.description.abstractCOVID-19 vaccinations have been accompanied by reports of inflammatory uveitis. Herein, we report the first case of bilateral persistent placoid maculopathy (PPM) following COVID-19 vaccinations in a previously healthy 58-year-old man who presented with bilateral decrease in vision approximately 2 weeks after the second dose of AstraZenaca® ChAdOx1-S/nCoV-19 vaccine. Fundus examination revealed bilateral well-delineated whitish plaque-like macular lesions involving the fovea. Clinical and multimodal imaging findings were suggestive of PPM. Infective and autoimmune screen were all negative except for a raised MPO-ANCA. Medical review excluded systemic autoimmune and infectious diseases. Patient was monitored closely and his visual acuity improved and stabilised after a tapering regime of oral prednisolone. Mycophenolate mofetil was given as long-term steroid sparing immunosuppression. Our case demonstrated a likely localised autoimmune inflammatory response to the COVID-19 vaccine affecting choriocapillaris. Further research is needed to clarify the association between COVID-19 vaccines and inflammatory placoid lesions of the retina.en_US
rioxxterms.funder.project94a427429a5bcfef7dd04c33360d80cden_US


This item appears in the following Collection(s)

Show simple item record